Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/586,023-Conf. #1717	
11	VEORMATION	I DI	SCLOSURE	Filing Date	July 14, 2006	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Elisabeth Woltering	
				Art Unit	1614	
	(Use as many she	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	BHC 031067 83382(303989)	

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA*	US-4,012,413	03-15-1977	Hester, Jr.			
	AB*	US-4,374,842	02-22-1983	Hirai et al.			
	AC*	US-4,476,133	10-09-1984	Hirai et al.			
-	AD*	US-3,812,259	05-21-1974	Collins			
-							

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear					
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY			T_{e}				
	ва	JP-05345785-A	12-27-1993	Yoshitomi Pharmaceutical et al.						
	BB	EP-875247-A1	11-04-1998	Tno						
	вс	EP-638560-A1	02-15-1995	Yoshitomi Pharmaceutical et al.						

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with §1.6(a)(4) on the date indicated below.

Dated: October 16, 2009 Electronic Signature for Gabriel J. McCool: /Gabriel J. McCool/

Approved for use through 07/31/2012. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	ostitute for form 1449/PTO			Complete if Known		
				Application Number	10/586,023-Conf. #1717	
	VEORMATION	1 DI	SCLOSURE	Filing Date	July 14, 2006	
l s	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Elisabeth Woltering	
				Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	Sheet 2 of 3		Attorney Docket Number	BHC 031067 83382(303989)		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	СА	G. Assmann et al.: "The Munster Heart Study (PROCAM)," European Heart Journal, Vol. 19, Supp. A., 1998, pp. A2-A11	
	СВ	N. S. Watson et al.: "7 Squalene Synthase Inhibitors: Their Potential as Hypocholesterolaemic Agents," Progress in Medicinal Chemistry, Vol. 33, 1996, pp. 331-378	
	СС	H. Hiyoshi et al.: "Squalene Synthase Inhibitors Reduce Plasma Triglyceride Through a Low- Density Lipoprotein Receptor-Independent Mechanism," European Journal of Pharmacology, Vol. 431, 2001, pp. 345-352	
	CD	J. B. Jian et al.: "Synthesis and Biological Evaluation of 2-Styrylquinazolin-4(3 <i>H</i>)-ones, a New Class of Antimitotic Anticancer Agents which Inhibit Tubulin Polymerization," J. Med. Chem., Vol. 33, 1990, pp. 171-1728	
	CE	T. Miki et al.: "Synthesis of Novel 4,1-Benzoxazepine Derivatives as Squalene Synthase Inhibitors and their Inhibition of Cholesterol Synthesis," J. Med. Chem., Vol. 45, 2002, pp. 4571-4580	
	CF	D. Papa et al.: "β-Aroylacrylic Acids," J. Amer. Chem. Soc., Vol. 70, 1948, pp. 3356-3360	
	CG	T. Miki et al.: "Novel 4,1-Benzoxazepine Derivatives with Potent Squalene Synthase Inhibitory Activities," Bioorganic & Medicinal Chemistry, Vol. 10, 2002, pp. 401-414	
	СН	D. Ma et al.: "Total Synthesis of (2 <i>S</i> ,2 <i>S</i> ,4 <i>R</i>)-Plakoridine A," Tetrahedron Letters, Vol. 41, 2000, pp. 1947-1950	
	CI	K. H. Weber et al.: "Bistriazolooxazepine under -thiazepine, Pyrazolotriazolothiazepine und Thienotrazolooxazepine," Liebigs Ann. Chem., 1978, pp. 1250-1256	
	CJ	I W. Duncan et al.: "Determination of Free, Total, and Esterified Cholesterol by High- Performance Liquid Chromatography," Journal of Chromatography, Vol. 162, 1979, pp. 281- 292	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/586,023-Conf. #1717	
11	IFORMATION	1 DI	SCLOSURE	Filing Date	July 14, 2006	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Elisabeth Woltering	
				Art Unit	N/A	
	(Use as many sh	eets as	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	3	Attorney Docket Number	BHC 031067 83382(303989)	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	CK	H. Bischoff et al.: "Cerivastatin: Pharmacology of a Novel Synthetic and Highly Active HMG-CoA Reductase Inhibitor," Atherosclerosis, Vol 135, 1997, pp. 119-130					
			1 === 1				

Signature Considered *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Examiner

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.